Cancer Cachexia Market to Reach USD 2.93 Billion by 2027; Favorable Reimbursement Policies to Drive Growth in North America

The global cancer cachexia market size is projected to reach USD 2.93 billion by 2027. It is expected to gain momentum from the ever-increasing prevalence of cancer and cachexia. It is, thereby presenting a huge patient pool looking for efficient treatment options. Fortune Business Insights™ provided this information in a recent report, titled, “Cancer Cachexia Market Size, Share & Covid-19 Impact Analysis, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The report further mentions that the market stood at USD 2.02 billion in 2019. However, it is set to exhibit a CAGR of 4.8% during the forecast period between 2020 to 2027.

Helsinn Introduces ‘Helsinn Cares’ Patient Support Services in the U.S.

In February 2017, Helsinn unveiled its patient support services named ‘Helsinn Cares’ for Akynzeo® in the U.S. The newly launched service showcased the latest goal of the company to help patients in gaining access to novel medicines. The company is set to make patient access efficient across its existing and upcoming products.

As per one of the company officials, “Helsinn recognized that not all patients gain access to those medicines that are capable of easing the burden of the side effects of chemotherapy effectively. This is very challenging. But our new Helsinn Cares is specifically developed to support every patient in the U.S. to get access to such medicines.”

Persistent Clinical Trials of New Drugs to Propel Growth

Presently, only a few drugs, namely, progestogens and corticosteroids are available in the market for the patients worldwide. During the clinical trials, the above-mentioned drugs have proved to be very efficient in treating cancer cachexia. But there is still a gap in the outcomes. Not many drugs have been specifically approved by the regulatory bodies for the treatment of this wasting syndrome. To fulfill the gap, several manufacturers are investing huge sums in the research and development activities to produce new drugs. They are then conducting extensive clinical trials to receive fast-track approvals for marketing and distributing those drugs in the market.

However, the expensive nature of treatment of this condition may hamper the cancer cachexia market growth during the forthcoming period. Apart from that, the outbreak of the COVID-19 pandemic is affecting a large number of patients suffering from cancer. Hence, numerous medical associations are suggesting the usage of Telehealth for efficient patient care.

https://www.fortunebusinessinsights.com/cancer-cachexia-market-103262

Key Players Focus on Bagging Fast-track Approvals to Gain Competitive Edge

The market houses very few companies because of the lack of approved therapeutics for cancer cachexia treatment. This is opening doors to many opportunities for them to conduct research and development activities for producing new drugs. They are also focusing on bagging approvals from the authorities to distribute and market the products.

Fortune Business Insights™ lists out the names of all the reputed providers of cancer cachexia operating in the global market. They are as follows:

• Bristol-Myers Squibb Company, New York, U.S.


• ANI Pharmaceuticals, Inc., Baudette, U.S.


• Merck & Co., Inc., Kenilworth, U.S.


• Hikma Pharmaceuticals PLC, London, U.K.


• Mylan N.V., Pennsylvania, U.S.


• AbbVie, Inc., North Chicago, U.S.


• Pfizer Inc., New York, U.S.


• Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel

A Noteworthy Industry Development-

• March 2019: Helsinn Group, a reputed provider of quality cancer care products based in Switzerland, declared that the first patient received the dose of anamorelin during its Phase III trial program. This program aims at treating anorexia and weight loss in patients with advanced non-small cell lung cancer (NSCLC) with cachexia.

Further Report Findings-

• Based on product, the progestogens segment is anticipated to account for the largest market share and dominate throughout the forthcoming years. This growth is attributable to their cost-effective nature and higher efficiency to treat cancer cachexia, unlike the other products.


• North America held USD 0.80 billion in 2019 in terms of revenue and would lead the market in the near future. It is set to occur because of the presence of favorable reimbursement policies, as well as the increasing affordability of patients residing in the developed nations, such as the U.S. and Canada.


• Europe is expected to grow significantly stoked by the high demand for cancer cachexia therapeutics from the patients living with head & neck, colorectal, and lung cancers.

The global market can be segmented in the following way: